Boston Medical Center Corporation

Boston Medical Center Corporation was paid $768.48M by Medicaid between Jan 2018 and Dec 2024, across 1247 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 9.8% of everything it billed.

Compared with peers

Next to other General Acute Care Hospital providers in Massachusetts

Rank by total paid#1 of 66

Median peer was paid$29.11M

This provider vs. median26×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	1,939,721	$108.25M
2019	2,006,052	$90.80M
2020	1,649,145	$85.72M
2021	2,196,195	$109.98M
2022	2,343,432	$129.26M
2023	2,328,144	$139.46M
2024incomplete	1,994,456	$105.02M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
99214	Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity	9.8%	558,247	493,214	$75.16M
99213	Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity	7.5%	440,043	390,235	$57.41M
96361	Intravenous infusion, hydration; each additional hour	4.2%	80,652	63,955	$32.06M
99285	Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life	3.8%	149,366	131,151	$29.40M
99283	Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity	3.7%	168,222	149,761	$28.33M
99215	Doctor's office visit, returning patient (complex)Prolong outpt/office vis	3.6%	190,774	173,688	$28.01M
99284	Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity	2.8%	123,361	111,075	$21.67M
G0463	Hospital outpatient clinic visit for assessment and management of a patient	2.3%	523,396	373,699	$17.75M
99212	Office or other outpatient visit for the evaluation and management of an established patient, straightforward	1.5%	96,271	84,047	$11.15M
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	1.3%	35,771	33,981	$10.33M
99211	Office or other outpatient visit for the evaluation and management of an established patient, minimal severity	1.3%	83,404	65,497	$10.06M
99204	Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity	1.3%	82,693	79,986	$10.02M

1235 more codes

J9271	Injection, pembrolizumab, 1 mg	1.3%	2,320	$9.84M
99203	Doctor's office visit, new patient (routine)	1.2%	78,003	$8.92M
97110	Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion	1.0%	197,189	$7.70M
96413	Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance	<1%	31,453	$7.58M
Q5103	Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg	<1%	3,647	$7.10M
T1040	Medicaid certified community behavioral health clinic services, per diem	<1%	29,380	$6.87M
99282	Emergency department visit for the evaluation and management, low to moderate severity	<1%	44,193	$6.77M
43239	Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple	<1%	9,506	$6.58M
J2357	Injection, omalizumab, 5 mg	<1%	5,504	$6.24M
74177	Computed tomography, abdomen and pelvis; with contrast material	<1%	33,564	$6.13M
G0378	Hospital observation service, per hour	<1%	69,899	$5.83M
45385	Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s)	<1%	8,406	$5.51M
45378	Colonoscopy, flexible; diagnostic, including collection of specimen(s)	<1%	9,140	$5.30M
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	<1%	85,922	$5.28M
59025	Fetal non-stress test	<1%	17,956	$5.25M
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	<1%	118,190	$5.17M
93306	Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete	<1%	27,747	$5.17M
Q9992	Injection, buprenorphine extended-release (sublocade), greater than 100 mg	<1%	3,215	$4.79M
J9144	Injection, daratumumab, 10 mg and hyaluronidase-fihj	<1%	1,902	$4.38M
62323		<1%	9,077	$4.35M
96110	Developmental screening, with scoring and documentation, per standardized instrument	<1%	30,907	$4.30M
92014	Ophthalmological services: medical examination and evaluation, comprehensive, established patient	<1%	46,817	$4.27M
45380	Colonoscopy, flexible; with biopsy, single or multiple	<1%	7,162	$4.18M
70553	Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences	<1%	13,133	$3.99M
99205	Prolong outpt/office vis	<1%	28,908	$3.86M
95810	Polysomnography; sleep staging with 4 or more additional parameters	<1%	5,531	$3.85M
70450	Computed tomography, head or brain; without contrast material	<1%	27,148	$3.70M
96365	Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour	<1%	26,836	$3.63M
76700	Ultrasound, abdominal, real time with image documentation; complete	<1%	22,576	$3.47M
76816	Ultrasound, pregnant uterus, real time with image documentation, follow-up	<1%	23,766	$3.43M
96366	Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour	<1%	13,589	$3.38M
78815	Positron emission tomography (PET) for limited area imaging	<1%	4,622	$3.38M
87631		<1%	37,155	$3.33M
99391	Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year)	<1%	30,838	$3.26M
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	118,793	$3.12M
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	117,650	$3.07M
43235		<1%	3,979	$3.03M
96360	Intravenous infusion, hydration; initial, 31 minutes to 1 hour	<1%	25,221	$2.96M
76856	Ultrasound, pelvic (nonobstetric), real time with image documentation; complete	<1%	23,904	$2.89M
96415		<1%	7,312	$2.76M
66984	Extracapsular cataract removal with insertion of intraocular lens prosthesis	<1%	4,515	$2.73M
97140	Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage)	<1%	62,706	$2.52M
52000		<1%	3,973	$2.50M
J7307	Etonogestrel (contraceptive) implant system, including implant and supplies	<1%	2,121	$2.43M
92012	Ophthalmological services: medical examination and evaluation, intermediate, established patient	<1%	31,043	$2.32M
76830	Ultrasound, transvaginal	<1%	23,809	$2.31M
J2315	Injection, naltrexone, depot form, 1 mg	<1%	1,646	$2.31M
76801		<1%	19,439	$2.25M
70551	Magnetic resonance imaging, brain; without contrast material	<1%	8,686	$2.19M
87481		<1%	52,834	$2.19M
93971		<1%	14,655	$2.17M
20610		<1%	15,342	$2.15M
99392	Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years)	<1%	25,476	$2.15M
31575		<1%	10,980	$2.13M
92004	Ophthalmological services: medical examination and evaluation, comprehensive, new patient	<1%	23,348	$1.99M
J0585	Injection, onabotulinumtoxina, 1 unit	<1%	4,238	$1.86M
80053	Comprehensive metabolic panel	<1%	373,943	$1.85M
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	404,657	$1.83M
76770		<1%	11,805	$1.81M
47562		<1%	705	$1.78M
77386		<1%	7,570	$1.75M
97161		<1%	29,523	$1.73M
72148	Magnetic resonance imaging, lumbar spine; without contrast material	<1%	9,162	$1.60M
S9485	Crisis intervention mental health services, per diem	<1%	2,864	$1.60M
86481		<1%	26,321	$1.58M
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	<1%	60,827	$1.58M
99202	Office or other outpatient visit for the evaluation and management of a new patient, straightforward	<1%	13,570	$1.56M
77063	Screening digital breast tomosynthesis, bilateral	<1%	25,044	$1.56M
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	102,892	$1.55M
J9217	Leuprolide acetate (for depot suspension), 7.5 mg	<1%	3,126	$1.55M
76819	Fetal biophysical profile; without non-stress testing	<1%	13,389	$1.54M
95886		<1%	6,087	$1.53M
J0178	Injection, aflibercept, 1 mg	<1%	1,609	$1.52M
11043		<1%	3,437	$1.48M
77067	Screening mammography, bilateral, including computer-aided detection	<1%	37,048	$1.48M
97803		<1%	20,789	$1.48M
94640	Pressurized or nonpressurized inhalation treatment for acute airway obstruction	<1%	21,486	$1.48M
71275	Computed tomographic angiography, chest, with contrast material	<1%	6,878	$1.44M
31231		<1%	7,588	$1.44M
78452	Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress	<1%	2,960	$1.43M
76642		<1%	18,045	$1.39M
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	33,586	$1.37M
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	<1%	82,907	$1.37M
74183		<1%	4,931	$1.37M
Q5114	Injection, trastuzumab-dkst, biosimilar, (ogivri), 10 mg	<1%	1,046	$1.36M
76811	Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed	<1%	9,071	$1.34M
92552		<1%	19,145	$1.33M
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	50,190	$1.31M
87511		<1%	49,948	$1.30M
J1950	Injection, leuprolide acetate (for depot suspension), per 3.75 mg	<1%	1,094	$1.28M
87636	Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B	<1%	12,004	$1.28M
67028	Intravitreal injection of a pharmacologic agent	<1%	8,402	$1.27M
77412		<1%	8,539	$1.23M
19083		<1%	1,777	$1.22M
31579		<1%	2,984	$1.22M
70496		<1%	4,788	$1.22M
76536		<1%	13,631	$1.22M
96372	Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular	<1%	90,936	$1.20M
99393	Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years)	<1%	15,680	$1.19M
76805	Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation	<1%	8,357	$1.18M
72141		<1%	5,165	$1.17M
95811		<1%	2,266	$1.17M
76817	Ultrasound, pregnant uterus, real time with image documentation, transvaginal	<1%	19,485	$1.17M
J7298	Levonorgestrel-releasing intrauterine contraceptive system (mirena), 52 mg	<1%	852	$1.16M
82805		<1%	33,022	$1.14M
96402		<1%	4,712	$1.12M
83036	Hemoglobin; glycosylated (A1C)	<1%	216,352	$1.10M
74176	Computed tomography, abdomen and pelvis; without contrast material	<1%	5,860	$1.09M
71046	Radiologic examination, chest; 2 views	<1%	84,715	$1.07M
99395	Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years	<1%	11,565	$1.07M
99442		<1%	6,137	$1.07M
73721	Magnetic resonance imaging, any joint of lower extremity; without contrast material	<1%	4,597	$1.06M
84443	Thyroid stimulating hormone (TSH)	<1%	111,853	$1.05M
98967		<1%	8,834	$1.05M
J3380	Injection, vedolizumab, intravenous, 1 mg	<1%	328	$1.04M
20611		<1%	4,022	$1.01M
99443		<1%	5,701	$996K
Q5115	Injection, rituximab-abbs, biosimilar, (truxima), 10 mg	<1%	538	$973K
77300		<1%	2,078	$961K
Q9991	Injection, buprenorphine extended-release (sublocade), less than or equal to 100 mg	<1%	1,221	$945K
11042	Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm	<1%	4,425	$934K
93975		<1%	7,400	$931K
97802		<1%	14,923	$927K
99396	Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years	<1%	10,580	$927K
97535	Self-care/home management training, each 15 minutes	<1%	25,507	$926K
92567		<1%	21,677	$921K
87486		<1%	35,762	$916K
87581		<1%	35,764	$915K
76815	Ultrasound, pregnant uterus, real time with image documentation, limited	<1%	10,050	$913K
81220	CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants	<1%	2,605	$913K
76705	Ultrasound, abdominal, real time with image documentation; limited	<1%	8,328	$875K
87536		<1%	17,287	$874K
71250		<1%	11,054	$871K
36430		<1%	3,488	$853K
86803		<1%	82,730	$840K
90471	Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine	<1%	153,691	$801K
99394	Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years)	<1%	10,793	$800K
95004	Percutaneous tests with allergenic extracts, immediate type reaction	<1%	2,040	$799K
J0881	Injection, darbepoetin alfa, 1 microgram (non-esrd use)	<1%	4,859	$784K
87086	Culture, bacterial; quantitative colony count, urine	<1%	137,941	$760K
J0741	Injection, cabotegravir and rilpivirine, 2mg/3mg	<1%	560	$757K
95782		<1%	596	$752K
0241U	Neonatal screening for hereditary disorders, genomic sequence analysis panel	<1%	9,373	$752K
99281	Emergency department visit for the evaluation and management, self-limited or minor	<1%	5,226	$743K
97530	Therapeutic activities, direct patient contact, each 15 minutes	<1%	24,944	$740K
85027		<1%	175,395	$728K
11900		<1%	4,190	$711K
70544		<1%	3,409	$710K
72197		<1%	2,824	$709K
87902		<1%	4,578	$709K
93017		<1%	6,827	$707K
92015	Determination of refractive state	<1%	31,575	$703K
71260	Computed tomography, thorax, diagnostic; with contrast material	<1%	14,797	$671K
98966		<1%	5,738	$666K
92557		<1%	12,102	$659K
86780		<1%	66,883	$658K
58300		<1%	2,950	$642K
97010		<1%	16,662	$641K
93325		<1%	7,107	$638K
20550		<1%	4,676	$634K
11981		<1%	1,595	$632K
76813		<1%	7,383	$632K
80048	Basic metabolic panel (calcium, ionized)	<1%	155,644	$630K
87522	Neg quan hep c or qual rna	<1%	21,254	$629K
ATP14		<1%	68,578	$627K
93321		<1%	4,052	$617K
10060		<1%	3,285	$617K
11056		<1%	5,232	$608K
77336		<1%	8,647	$608K
92588		<1%	4,385	$605K
96374	Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance	<1%	89,770	$603K
84702		<1%	50,523	$602K
73221		<1%	2,793	$599K
77080		<1%	11,195	$597K
87624	Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types	<1%	28,207	$589K
92610		<1%	4,026	$585K
97162		<1%	11,064	$585K
91200		<1%	6,229	$578K
87507		<1%	2,143	$578K
0001A		<1%	16,741	$575K
82728		<1%	73,100	$572K
97112	Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination	<1%	12,941	$559K
94060		<1%	6,297	$554K
70491		<1%	4,295	$545K
93970		<1%	3,104	$545K
84484		<1%	70,022	$544K
77066	Tomosynthesis, mammo	<1%	14,327	$542K
96401		<1%	5,893	$541K
98968		<1%	4,813	$537K
74178		<1%	2,784	$534K
96409		<1%	1,376	$531K
42820	Tonsillectomy and adenoidectomy; younger than age 12	<1%	235	$530K
99291	Critical care, evaluation and management of the critically ill patient, first 30-74 minutes	<1%	2,509	$514K
70355		<1%	10,584	$511K
77065	Tomosynthesis, mammo	<1%	12,007	$506K
J9299	Injection, nivolumab, 1 mg	<1%	284	$504K
76882		<1%	5,200	$499K
83970		<1%	32,478	$497K
90756		<1%	22,723	$491K
99385		<1%	4,970	$491K
95816		<1%	1,586	$481K
20553		<1%	3,100	$477K
80061	Lipid panel	<1%	153,458	$477K
86141		<1%	58,271	$472K
99441		<1%	2,828	$469K
80050	General health panel	<1%	33,513	$465K
76818		<1%	3,734	$465K
76857		<1%	5,383	$464K
11721		<1%	19,181	$463K
90715		<1%	23,737	$460K
90834	Psychotherapy session, about 45 minutes	<1%	25,667	$459K
0011A		<1%	20,227	$458K
77062		<1%	3,736	$453K
62321		<1%	790	$450K
97165		<1%	6,171	$450K
84703		<1%	79,696	$447K
93005	Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report	<1%	206,273	$439K
95819		<1%	1,537	$433K
J7297	Levonorgestrel-releasing intrauterine contraceptive system (liletta), 52 mg	<1%	539	$426K
70486		<1%	6,029	$423K
76881		<1%	3,947	$422K
91322		<1%	6,515	$420K
83880		<1%	24,575	$418K
88305	Level IV - Surgical pathology, gross and microscopic examination	<1%	51,271	$418K
86850		<1%	72,986	$417K
76870		<1%	3,993	$415K
83550		<1%	78,203	$414K
88142		<1%	32,487	$413K
96127		<1%	8,998	$402K
J1750	Injection, iron dextran, 50 mg	<1%	5,389	$401K
96416		<1%	2,197	$399K
93303	Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study	<1%	1,382	$397K
58301		<1%	2,054	$374K
64405		<1%	1,115	$374K
77061		<1%	2,847	$362K
11102		<1%	1,016	$361K
17110		<1%	2,278	$358K
J1050	Injection, medroxyprogesterone acetate, 1 mg	<1%	8,435	$354K
76820		<1%	7,883	$354K
A9576	Injection, gadoteridol, (prohance multipack), per ml	<1%	7,874	$348K
86360		<1%	14,046	$343K
82607		<1%	45,929	$339K
94726		<1%	7,889	$335K
12001		<1%	1,449	$331K
81001		<1%	162,633	$328K
Q3014	Telehealth originating site facility fee	<1%	81,028	$319K
96367		<1%	5,007	$315K
83540		<1%	79,228	$311K
44970		<1%	87	$310K
87340		<1%	46,762	$309K
77334		<1%	2,088	$306K
87641		<1%	17,709	$303K
92083		<1%	14,920	$301K
83735		<1%	86,913	$299K
83605		<1%	39,519	$297K
51741		<1%	4,274	$288K
86359		<1%	14,876	$285K
90651		<1%	6,047	$285K
J9306	Injection, pertuzumab, 1 mg	<1%	251	$285K
83690		<1%	59,631	$284K
J1745	Injection, infliximab, excludes biosimilar, 10 mg	<1%	250	$278K
94010		<1%	5,405	$278K
58100		<1%	1,439	$277K
Q9967	Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml	<1%	31,474	$276K
88307		<1%	5,681	$276K
82330		<1%	33,831	$275K
86706		<1%	42,083	$273K
97166		<1%	4,032	$271K
92134		<1%	24,422	$270K
0002A		<1%	7,339	$267K
87563		<1%	12,586	$266K
57454		<1%	840	$263K
94729		<1%	7,443	$257K
72100		<1%	13,653	$255K
11055		<1%	1,925	$253K
71271		<1%	5,808	$252K
73630		<1%	22,636	$249K
96375	Therapeutic injection; each additional sequential IV push	<1%	64,382	$247K
92507	Treatment of speech, language, voice, communication, and/or auditory processing disorder	<1%	2,941	$245K
11982		<1%	1,187	$244K
J3010	Injection, fentanyl citrate, 0.1 mg	<1%	72,155	$242K
G0297	Low dose ct scan (ldct) for lung cancer screening	<1%	2,407	$241K
70547		<1%	1,741	$239K
0064A		<1%	9,962	$234K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	<1%	9,848	$230K
73030		<1%	17,665	$229K
64493		<1%	704	$229K
Q5108	Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg	<1%	138	$226K
99386		<1%	2,766	$224K
97116		<1%	9,076	$224K
90677		<1%	8,637	$224K
85610		<1%	98,854	$223K
86003		<1%	5,435	$221K
73564		<1%	15,657	$220K
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	<1%	277	$218K
90791	Psychiatric diagnostic evaluation	<1%	6,978	$217K
J1885	Injection, ketorolac tromethamine, per 15 mg	<1%	73,670	$216K
77280		<1%	2,145	$214K
J2405	Injection, ondansetron hydrochloride, per 1 mg	<1%	74,268	$213K
0012A		<1%	8,285	$212K
82746		<1%	29,825	$212K
51728		<1%	1,008	$212K
0004A		<1%	6,650	$211K
12011		<1%	889	$209K
78999		<1%	3,890	$208K
ATP08		<1%	29,740	$208K
90480		<1%	7,911	$206K
81329		<1%	2,070	$205K
J2704	Injection, propofol, 10 mg	<1%	71,675	$205K
J1100	Injection, dexamethasone sodium phosphate, 1 mg	<1%	39,276	$203K
76942		<1%	4,026	$200K
77014		<1%	22,160	$199K
82784		<1%	20,274	$198K
G0382	Level 3 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment)	<1%	5,021	$197K
84403		<1%	12,873	$197K
J2426	Injection, paliperidone palmitate extended release (invega sustenna), 1 mg	<1%	450	$195K
90688		<1%	12,502	$194K
88342		<1%	8,257	$194K
92579		<1%	4,724	$194K
J0561	Injection, penicillin g benzathine, 100,000 units	<1%	1,925	$194K
90837	Psychotherapy session, about an hour	<1%	8,157	$193K
Q5104	Injection, infliximab-abda, biosimilar, (renflexis), 10 mg	<1%	103	$193K
84439		<1%	35,420	$191K
87502	Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets	<1%	3,356	$190K
72125	Computed tomography, cervical spine; without contrast material	<1%	11,791	$189K
86704		<1%	27,188	$189K
J1437	Injection, ferric derisomaltose, 10 mg	<1%	220	$183K
70498		<1%	4,124	$182K
G0279	Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066)	<1%	16,499	$182K
85730		<1%	37,138	$181K
J0574	Buprenorphine/naloxone, oral, greater than 6 mg, but less than or equal to 10 mg buprenorphine	<1%	6,501	$180K
83021		<1%	12,920	$179K
87480		<1%	10,294	$178K
86900		<1%	73,504	$177K
87510		<1%	10,300	$177K
87660		<1%	10,298	$176K
J2250	Injection, midazolam hydrochloride, per 1 mg	<1%	58,492	$176K
74174		<1%	1,544	$175K
73610		<1%	17,696	$174K
69210		<1%	5,021	$173K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	4,151	$172K
87077		<1%	29,410	$172K
J1650	Injection, enoxaparin sodium, 10 mg	<1%	17,307	$170K
72158		<1%	939	$170K
J0897	Injection, denosumab, 1 mg	<1%	328	$169K
90746		<1%	8,262	$169K
73130		<1%	19,089	$168K
D7140	Extraction, erupted tooth or exposed root	<1%	706	$168K
84153		<1%	22,263	$167K
87430		<1%	13,811	$165K
93923		<1%	2,210	$164K
10005		<1%	766	$164K
86901		<1%	73,877	$163K
86480		<1%	3,817	$161K
81229		<1%	188	$161K
82274		<1%	19,638	$161K
64615		<1%	607	$160K
46607		<1%	296	$160K
86762		<1%	15,455	$157K
86787		<1%	17,007	$157K
U0002	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc	<1%	4,123	$155K
92504		<1%	6,244	$155K
J3490	Unclassified drugs	<1%	9,272	$152K
78431		<1%	138	$151K
84425		<1%	14,526	$148K
87186		<1%	24,997	$148K
J0690	Injection, cefazolin sodium, 500 mg	<1%	29,250	$147K
J0131	Injection, acetaminophen, not otherwise specified,10 mg	<1%	4,994	$147K
90832	Psychotherapy session, about 30 minutes	<1%	10,960	$147K
52356		<1%	45	$146K
82948		<1%	39,883	$146K
D7230		<1%	290	$145K
Q0139	Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (for esrd on dialysis)	<1%	624	$144K
J9312	Injection, rituximab, 10 mg	<1%	121	$144K
88112		<1%	5,795	$142K
73560		<1%	13,527	$141K
90674		<1%	7,064	$139K
ATP15		<1%	16,328	$138K
87517		<1%	5,718	$137K
87040		<1%	12,271	$136K
87081		<1%	23,942	$135K
80069		<1%	42,682	$134K
92553		<1%	4,099	$134K
77295		<1%	331	$134K
G0108	Diabetes outpatient self-management training services, individual, per 30 minutes	<1%	2,543	$134K
74230		<1%	912	$133K
36561		<1%	170	$132K
J0696	Injection, ceftriaxone sodium, per 250 mg	<1%	21,620	$131K
J1644	Injection, heparin sodium, per 1000 units	<1%	29,775	$130K
92133		<1%	12,914	$130K
12002		<1%	595	$129K
J1815	Injection, insulin, per 5 units	<1%	35,332	$127K
J9041	Injection, bortezomib, 0.1 mg	<1%	319	$127K
J0702	Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg	<1%	8,489	$126K
71045	Radiologic examination, chest; single view	<1%	30,789	$125K
82105		<1%	12,326	$124K
G0270	Medical nutrition therapy; reassessment and subsequent intervention(s) following second referral in same year for change in diagnosis, medical condition or treatment regimen (including additional hours needed for renal disease), individual, face to face with the patient, each 15 minutes	<1%	8,262	$123K
86708		<1%	14,736	$121K
72040		<1%	6,120	$119K
82947		<1%	60,707	$118K
G0008	Administration of influenza virus vaccine	<1%	21,298	$117K
D7240	Removal of impacted tooth - completely bony	<1%	269	$116K
82670		<1%	6,527	$116K
93798		<1%	2,780	$115K
70543		<1%	371	$114K
92020		<1%	1,569	$114K
83001		<1%	9,432	$113K
J1642	Injection, heparin sodium, (heparin lock flush), per 10 units	<1%	13,309	$112K
82043		<1%	43,052	$111K
77290		<1%	675	$110K
72156		<1%	459	$110K
95115		<1%	3,885	$110K
19318		<1%	39	$109K
84146		<1%	9,158	$109K
78803		<1%	462	$109K
99218		<1%	977	$108K
81025		<1%	20,671	$106K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	<1%	2,402	$106K
90472	Immunization administration, each additional vaccine (list separately)	<1%	55,091	$105K
69436	Tympanostomy (requiring insertion of ventilating tube), general anesthesia	<1%	56	$104K
93880		<1%	942	$104K
87428		<1%	1,777	$104K
0124A		<1%	3,864	$104K
95911		<1%	1,439	$102K
11104		<1%	276	$102K
11100		<1%	425	$101K
73502		<1%	10,344	$101K
95912		<1%	1,113	$100K
99201		<1%	840	$100K
82951		<1%	8,831	$99K
10061		<1%	565	$97K
88341		<1%	5,234	$97K
84480		<1%	12,286	$96K
73110		<1%	9,801	$96K
97804		<1%	989	$95K
95028		<1%	477	$94K
84270		<1%	6,281	$92K
72110		<1%	7,417	$92K
36415	Collection of venous blood by venipuncture	<1%	143,329	$91K
20605		<1%	707	$91K
86334		<1%	10,912	$90K
76775		<1%	743	$89K
90792	Psychiatric diagnostic evaluation with medical services	<1%	2,861	$89K
86920		<1%	877	$88K
93351		<1%	3,054	$88K
90662		<1%	11,352	$87K
82962		<1%	55,476	$87K
80074		<1%	2,761	$86K
97810		<1%	1,246	$86K
76937		<1%	2,107	$85K
20526		<1%	766	$85K
93308		<1%	508	$84K
85652		<1%	50,880	$83K
84445		<1%	2,938	$83K
ATP17		<1%	10,589	$83K
94618		<1%	811	$83K
95913		<1%	912	$82K
66761		<1%	123	$82K
86160		<1%	6,981	$82K
0134A		<1%	4,400	$81K
83013		<1%	1,680	$79K
88173		<1%	2,809	$77K
78492		<1%	59	$77K
J9263	Injection, oxaliplatin, 0.5 mg	<1%	1,428	$77K
80076		<1%	21,101	$76K
0071A		<1%	1,914	$76K
86038		<1%	11,381	$76K
0072A		<1%	1,706	$76K
19499		<1%	95	$75K
J0791	Injection, crizanlizumab-tmca, 5 mg	<1%	122	$75K
83002		<1%	5,781	$75K
J7120	Ringers lactate infusion, up to 1000 cc	<1%	29,007	$74K
87150		<1%	2,388	$74K
0031A		<1%	2,651	$74K
85379		<1%	10,842	$74K
82570		<1%	30,673	$74K
82378		<1%	10,012	$74K
92136		<1%	2,641	$73K
86765		<1%	9,133	$72K
J3489	Injection, zoledronic acid, 1 mg	<1%	2,866	$72K
99381		<1%	465	$71K
51784		<1%	622	$71K
87799		<1%	5,157	$71K
P9040	Red blood cells, leukocytes reduced, irradiated, each unit	<1%	2,178	$70K
86735		<1%	8,757	$70K
J1170	Injection, hydromorphone, up to 4 mg	<1%	27,924	$69K
96411		<1%	3,460	$69K
H2016	Community support for mental illness or disability, billed per day	<1%	2,481	$69K
86923		<1%	3,089	$68K
72052		<1%	3,360	$68K
90732		<1%	4,663	$67K
92611		<1%	851	$67K
87070		<1%	11,512	$67K
93296		<1%	2,322	$66K
92526		<1%	800	$65K
82248		<1%	35,121	$64K
81003		<1%	42,738	$64K
82565		<1%	30,605	$64K
83525		<1%	8,692	$62K
95806		<1%	242	$62K
77387		<1%	2,908	$62K
96376		<1%	23,077	$61K
92558		<1%	3,402	$61K
83883		<1%	9,950	$60K
87529		<1%	2,390	$60K
86235		<1%	3,536	$60K
J3471	Injection, hyaluronidase, ovine, preservative free, per 1 usp unit (up to 999 usp units)	<1%	789	$60K
88185		<1%	454	$59K
87535		<1%	2,442	$58K
74240		<1%	348	$58K
87338		<1%	5,987	$58K
20551		<1%	422	$58K
ATP10		<1%	8,720	$57K
95117		<1%	1,734	$57K
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	<1%	554	$57K
C9257	Injection, bevacizumab, 0.25 mg	<1%	4,515	$57K
J2270	Injection, morphine sulfate, up to 10 mg	<1%	22,035	$57K
76604		<1%	796	$57K
82785		<1%	5,051	$57K
88304		<1%	11,282	$56K
90694		<1%	4,574	$55K
87538		<1%	2,260	$54K
51785		<1%	504	$54K
84156		<1%	31,980	$53K
J0485	Injection, belatacept, 1 mg	<1%	119	$53K
64483		<1%	94	$53K
73562		<1%	7,501	$53K
G0271	Medical nutrition therapy, reassessment and subsequent intervention(s) following second referral in same year for change in diagnosis, medical condition, or treatment regimen (including additional hours needed for renal disease), group (2 or more individuals), each 30 minutes	<1%	1,872	$53K
87640		<1%	3,890	$52K
Q5118	Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg	<1%	347	$52K
93280		<1%	1,842	$52K
99397		<1%	1,018	$52K
64721		<1%	91	$51K
84145		<1%	3,408	$51K
87088		<1%	9,632	$51K
84165		<1%	11,588	$51K
11720		<1%	1,629	$50K
84100		<1%	37,071	$50K
73140		<1%	4,291	$49K
77072		<1%	970	$48K
80177		<1%	5,465	$48K
90734		<1%	2,200	$48K
73590		<1%	7,129	$47K
99495		<1%	997	$47K
J1439	Injection, ferric carboxymaltose, 1 mg	<1%	56	$46K
58558		<1%	76	$46K
70480		<1%	578	$46K
77049		<1%	264	$45K
ATP03		<1%	20,006	$45K
J7644	Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram	<1%	12,041	$44K
C8929	Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography	<1%	326	$44K
92555		<1%	4,676	$43K
84163		<1%	3,116	$43K
83516		<1%	4,516	$43K
Q0162	Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen	<1%	13,069	$42K
J9035	Injection, bevacizumab, 10 mg	<1%	69	$42K
90632		<1%	1,770	$42K
99496		<1%	729	$41K
81596		<1%	841	$41K
C9803	Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	<1%	22,152	$41K
90670		<1%	9,863	$40K
92002		<1%	610	$40K
86800		<1%	5,062	$40K
58661		<1%	82	$40K
90658		<1%	2,215	$39K
90853	Group psychotherapy (other than of a multiple-family group)	<1%	2,419	$39K
90739		<1%	2,049	$39K
G0381	Level 2 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment)	<1%	1,239	$39K
J3301	Injection, triamcinolone acetonide, not otherwise specified, 10 mg	<1%	23,910	$38K
86376		<1%	4,340	$38K
97164		<1%	865	$38K
73080		<1%	4,723	$37K
86255		<1%	5,244	$37K
J1200	Injection, diphenhydramine hcl, up to 50 mg	<1%	11,810	$37K
82533		<1%	3,903	$37K
J9310	Injection, rituximab, 100 mg	<1%	58	$37K
49650		<1%	32	$36K
82550		<1%	19,412	$36K
96111		<1%	426	$36K
90620		<1%	194	$36K
74018		<1%	2,882	$36K
77073		<1%	6,381	$36K
85045		<1%	14,915	$36K
82088		<1%	1,936	$36K
80164		<1%	4,344	$35K
J2370	Injection, phenylephrine hcl, up to 1 ml	<1%	7,669	$35K
80197		<1%	9,644	$35K
83519		<1%	3,008	$34K
0003A		<1%	1,129	$34K
20552		<1%	208	$34K
87880	Infectious agent antigen detection by immunoassay; Streptococcus, group A	<1%	2,622	$34K
87205		<1%	12,028	$34K
ATP16		<1%	3,946	$34K
97811		<1%	1,038	$33K
83521		<1%	5,963	$33K
92587		<1%	159	$33K
92582		<1%	1,154	$33K
83921		<1%	3,853	$32K
92250		<1%	3,937	$32K
30520		<1%	26	$32K
96112		<1%	2,251	$32K
77301		<1%	72	$32K
96910		<1%	763	$32K
99383		<1%	291	$32K
82525		<1%	5,288	$31K
84630		<1%	5,578	$31K
0013A		<1%	1,578	$31K
78306		<1%	244	$30K
Q5111	Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg	<1%	71	$30K
73700		<1%	434	$30K
72131		<1%	732	$30K
ATP11		<1%	4,448	$30K
92025		<1%	1,538	$30K
96417		<1%	6,989	$29K
J3370	Injection, vancomycin hcl, 500 mg	<1%	13,777	$29K
J2060	Injection, lorazepam, 2 mg	<1%	12,066	$29K
82077		<1%	5,627	$29K
67228		<1%	75	$29K
84436		<1%	7,259	$29K
95910		<1%	333	$28K
11730		<1%	356	$28K
86870		<1%	386	$28K
86677		<1%	3,193	$28K
74019		<1%	2,328	$27K
84134		<1%	4,705	$27K
55700		<1%	79	$27K
G0472	Hepatitis c antibody screening, for individual at high risk and other covered indication(s)	<1%	11,869	$27K
82627		<1%	1,726	$26K
72070		<1%	1,747	$26K
84460		<1%	19,964	$26K
A9552	Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries	<1%	3,658	$26K
86753		<1%	2,920	$26K
S0020	Injection, bupivicaine hydrochloride, 30 ml	<1%	2,530	$26K
73090		<1%	4,747	$26K
0054A		<1%	771	$26K
83721		<1%	6,108	$26K
99382		<1%	209	$26K
J7512	Prednisone, immediate release or delayed release, oral, 1 mg	<1%	14,156	$26K
84450		<1%	18,778	$25K
73552		<1%	3,104	$25K
84432		<1%	3,511	$25K
64450		<1%	173	$25K
90686		<1%	18,523	$25K
G2066	Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results	<1%	935	$25K
84166		<1%	3,319	$25K
90653		<1%	1,742	$25K
J1726	Injection, hydroxyprogesterone caproate, (makena), 10 mg	<1%	297	$25K
86902		<1%	489	$25K
J2001	Injection, lidocaine hcl for intravenous infusion, 10 mg	<1%	23,592	$25K
87075		<1%	4,051	$24K
83615		<1%	15,883	$24K
J1630	Injection, haloperidol, up to 5 mg	<1%	10,795	$24K
29125		<1%	272	$24K
72170		<1%	2,400	$23K
84305		<1%	1,613	$23K
86617		<1%	1,559	$23K
76000		<1%	469	$23K
25600		<1%	41	$23K
92060		<1%	1,282	$23K
87901		<1%	141	$22K
J7999	Compounded drug, not otherwise classified	<1%	3,109	$22K
46600		<1%	2,913	$22K
86200		<1%	3,625	$22K
Q9957	Injection, perflutren lipid microspheres, per ml	<1%	2,866	$22K
96040		<1%	3,012	$22K
J3411	Injection, thiamine hcl, 100 mg	<1%	4,083	$22K
J0248	Injection, remdesivir, 1 mg	<1%	86	$22K
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	<1%	282	$21K
86580		<1%	2,542	$21K
70487		<1%	179	$21K
84550		<1%	14,113	$21K
G0009	Administration of pneumococcal vaccine	<1%	4,232	$21K
99384		<1%	155	$21K
83014		<1%	4,039	$21K
H2015	Community support for mental illness or disability, per 15 minutes	<1%	1,153	$21K
80179		<1%	3,255	$21K
86147		<1%	1,561	$21K
86316		<1%	3,247	$20K
77001		<1%	541	$20K
96368		<1%	3,801	$20K
J3475	Injection, magnesium sulfate, per 500 mg	<1%	8,596	$20K
76998		<1%	310	$20K
0154A		<1%	432	$20K
90935	Hemodialysis procedure with single evaluation by a physician	<1%	271	$20K
84244		<1%	1,993	$20K
V2632	Posterior chamber intraocular lens	<1%	1,989	$20K
86039		<1%	3,239	$20K
82040		<1%	11,223	$20K
73060		<1%	3,635	$19K
82150		<1%	4,378	$19K
87184		<1%	4,209	$19K
86364		<1%	3,565	$18K
Q5126	Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg	<1%	92	$18K
83520		<1%	1,976	$18K
ATP07		<1%	2,536	$18K
73100		<1%	2,222	$18K
84479		<1%	5,082	$17K
64612		<1%	99	$17K
86665		<1%	857	$17K
J2777	Injection, faricimab-svoa, 0.1 mg	<1%	28	$17K
G0399	Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation	<1%	230	$17K
J0171	Injection, adrenalin, epinephrine, 0.1 mg	<1%	4,479	$17K
83789		<1%	1,070	$16K
88313		<1%	1,332	$16K
87102		<1%	3,092	$16K
J1040	Injection, methylprednisolone acetate, 80 mg	<1%	5,851	$16K
86431		<1%	5,677	$16K
0081A		<1%	533	$16K
87015		<1%	3,841	$16K
72082		<1%	727	$16K
90833	Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on)	<1%	792	$16K
86592		<1%	5,641	$16K
J2785	Injection, regadenoson, 0.1 mg	<1%	3,201	$16K
19081		<1%	13	$16K
J0572	Buprenorphine/naloxone, oral, less than or equal to 3 mg buprenorphine	<1%	412	$16K
ATP09		<1%	2,137	$15K
0052A		<1%	366	$15K
86146		<1%	1,157	$15K
86696		<1%	1,289	$15K
J7300	Intrauterine copper contraceptive (paragard)	<1%	53	$15K
93304		<1%	54	$15K
J0401	Injection, aripiprazole (abilify maintena), 1 mg	<1%	12	$15K
86335		<1%	1,636	$15K
87632		<1%	106	$15K
87906		<1%	186	$15K
82024		<1%	720	$14K
80143		<1%	2,767	$14K
86682		<1%	1,904	$14K
86705		<1%	2,069	$14K
29581		<1%	113	$14K
82553		<1%	2,608	$14K
88184		<1%	635	$14K
82960		<1%	2,812	$13K
92524		<1%	197	$13K
ATP02		<1%	3,398	$13K
ATP18		<1%	1,698	$13K
M0220	Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring	<1%	329	$13K
65855		<1%	48	$13K
0051A		<1%	322	$13K
87900		<1%	141	$13K
G0121	Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk	<1%	169	$13K
76512		<1%	214	$13K
87116		<1%	2,298	$13K
84132		<1%	12,832	$13K
73523		<1%	948	$13K
J0665	Injection, bupivicaine, not otherwise specified, 0.5 mg	<1%	6,460	$13K
93282		<1%	466	$13K
96523		<1%	514	$13K
76885		<1%	92	$13K
84590		<1%	2,271	$13K
51600		<1%	96	$13K
85384		<1%	2,553	$13K
72146		<1%	129	$12K
J9355	Injection, trastuzumab, excludes biosimilar, 10 mg	<1%	45	$12K
G0103	Prostate cancer screening; prostate specific antigen test (psa)	<1%	2,523	$12K
89051		<1%	4,012	$12K
85018		<1%	8,487	$12K
15852		<1%	44	$12K
76514		<1%	507	$12K
99412		<1%	348	$12K
ATP04		<1%	2,141	$12K
90707		<1%	4,283	$12K
86021		<1%	1,464	$12K
82977		<1%	5,580	$11K
G0383	Level 4 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment)	<1%	352	$11K
72114		<1%	1,270	$11K
83010		<1%	1,871	$11K
A9581	Injection, gadoxetate disodium, 1 ml	<1%	628	$11K
84295		<1%	11,791	$11K
81002		<1%	5,417	$11K
91321		<1%	1,106	$11K
97597		<1%	85	$11K
Q0138	Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)	<1%	17	$10K
77338		<1%	72	$10K
83498		<1%	513	$10K
Q5123	Injection, rituximab-arrx, biosimilar, (riabni), 10 mg	<1%	68	$10K
81401		<1%	129	$10K
64494		<1%	361	$10K
A9500	Technetium tc-99m sestamibi, diagnostic, per study dose	<1%	2,160	$10K
86709		<1%	1,653	$10K
86645		<1%	934	$10K
0082A		<1%	230	$9K
91301		<1%	21,688	$9K
51798		<1%	4,255	$9K
J0137	Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg	<1%	972	$9K
82610		<1%	1,145	$9K
ATP05		<1%	1,411	$9K
86301		<1%	1,159	$9K
J1580	Injection, garamycin, gentamicin, up to 80 mg	<1%	3,309	$9K
G0010	Administration of hepatitis b vaccine	<1%	1,851	$9K
85705		<1%	1,732	$9K
82397		<1%	977	$9K
82435		<1%	10,994	$9K
90656		<1%	2,042	$9K
20600		<1%	54	$8K
86644		<1%	934	$8K
74241		<1%	28	$8K
J7626	Budesonide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, up to 0.5 mg	<1%	1,325	$8K
17000		<1%	153	$8K
72157		<1%	89	$8K
Q0166	Granisetron hydrochloride, 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 24 hour dosage regimen	<1%	12,886	$8K
93299		<1%	290	$8K
84466		<1%	1,436	$8K
87493		<1%	410	$8K
86695		<1%	945	$8K
J9045	Injection, carboplatin, 50 mg	<1%	1,828	$8K
C8930	Transthoracic echocardiography, with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation and report; including performance of continuous electrocardiographic monitoring, with physician supervision	<1%	64	$8K
90691		<1%	923	$8K
81455		<1%	14	$8K
86664		<1%	830	$8K
83993		<1%	682	$8K
86304		<1%	1,126	$8K
80230		<1%	350	$8K
J2997	Injection, alteplase recombinant, 1 mg	<1%	86	$7K
65426		<1%	12	$7K
J8540	Dexamethasone, oral, 0.25 mg	<1%	20,444	$7K
99173		<1%	461	$7K
72190		<1%	595	$7K
82310		<1%	4,974	$7K
J9171	Injection, docetaxel, 1 mg	<1%	69	$7K
76821		<1%	766	$7K
82247		<1%	3,932	$7K
87899		<1%	755	$7K
J0640	Injection, leucovorin calcium, per 50 mg	<1%	3,739	$7K
J2550	Injection, promethazine hcl, up to 50 mg	<1%	1,738	$7K
90714		<1%	562	$7K
82985		<1%	1,053	$7K
10022		<1%	78	$7K
95714		<1%	35	$7K
J2710	Injection, neostigmine methylsulfate, up to 0.5 mg	<1%	9,881	$7K
85613		<1%	1,234	$6K
A9575	Injection, gadoterate meglumine, 0.1 ml	<1%	1,039	$6K
82652		<1%	370	$6K
86336		<1%	447	$6K
J0330	Injection, succinylcholine chloride, up to 20 mg	<1%	9,712	$6K
A9595	Piflufolastat f-18, diagnostic, 1 millicurie	<1%	16	$6K
86663		<1%	777	$6K
73070		<1%	813	$6K
93225		<1%	175	$6K
86355		<1%	262	$6K
J0295	Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm	<1%	5,043	$6K
97022		<1%	116	$6K
90661		<1%	497	$6K
J1030	Injection, methylprednisolone acetate, 40 mg	<1%	3,554	$6K
90847	Family psychotherapy with the patient present, 50 minutes	<1%	89	$6K
87154		<1%	34	$6K
84520		<1%	4,667	$6K
86357		<1%	244	$6K
77003		<1%	87	$6K
0034A		<1%	362	$6K
83655		<1%	642	$6K
C1894	Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser	<1%	1,064	$6K
C1769	Guide wire	<1%	2,197	$6K
Q0163	Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen	<1%	15,395	$6K
42826		<1%	12	$6K
G0127	Trimming of dystrophic nails, any number	<1%	465	$6K
J2930	Injection, methylprednisolone sodium succinate, up to 125 mg	<1%	2,685	$5K
95716		<1%	14	$5K
90474		<1%	8,541	$5K
84681		<1%	519	$5K
90717		<1%	134	$5K
87426	Infectious agent antigen detection, SARS-CoV-2 (COVID-19)	<1%	202	$5K
82677		<1%	266	$5K
J9206	Injection, irinotecan, 20 mg	<1%	106	$5K
51701		<1%	723	$5K
83835		<1%	607	$5K
88300		<1%	1,114	$5K
J2310	Injection, naloxone hydrochloride, per 1 mg	<1%	193	$5K
J3420	Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg	<1%	5,209	$5K
57456		<1%	12	$5K
25605		<1%	13	$5K
74220		<1%	139	$5K
84300		<1%	1,626	$5K
J0135	Injection, adalimumab, 20 mg	<1%	333	$5K
92523		<1%	29	$4K
72072		<1%	189	$4K
82103		<1%	730	$4K
J0290	Injection, ampicillin sodium, 500 mg	<1%	865	$4K
86922		<1%	50	$4K
92550		<1%	14	$4K
M0243	Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring	<1%	19	$4K
73620		<1%	1,244	$4K
51797		<1%	889	$4K
86593		<1%	1,290	$4K
J7613	Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg	<1%	11,426	$4K
99407		<1%	314	$4K
86618		<1%	350	$4K
J9070	Cyclophosphamide, 100 mg	<1%	89	$4K
81243		<1%	77	$4K
77417		<1%	607	$4K
90716		<1%	4,380	$4K
Q5117	Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg	<1%	104	$4K
94660		<1%	16	$4K
87272		<1%	408	$3K
76098		<1%	309	$3K
0111A		<1%	211	$3K
D0150	Comprehensive oral evaluation - new or established patient	<1%	82	$3K
30140		<1%	14	$3K
97163		<1%	54	$3K
87046		<1%	449	$3K
83090		<1%	317	$3K
72128		<1%	150	$3K
87045		<1%	448	$3K
72195		<1%	12	$3K
78264		<1%	12	$3K
92585		<1%	12	$3K
J2765	Injection, metoclopramide hcl, up to 10 mg	<1%	13,382	$3K
90713		<1%	744	$3K
36475		<1%	13	$3K
80171		<1%	181	$3K
A4550	Surgical trays	<1%	3,317	$3K
82075		<1%	452	$3K
59200		<1%	13	$3K
0112A		<1%	76	$3K
86777		<1%	284	$3K
99404		<1%	30	$3K
J0689	Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg	<1%	1,035	$3K
A9555	Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries	<1%	250	$3K
36591		<1%	284	$3K
80299		<1%	347	$3K
84207		<1%	144	$3K
J1453	Injection, fosaprepitant, 1 mg	<1%	120	$3K
74181		<1%	17	$3K
87341		<1%	369	$3K
88311		<1%	1,216	$3K
76519		<1%	83	$3K
82390		<1%	431	$3K
51700		<1%	59	$3K
51702		<1%	265	$3K
82731		<1%	44	$3K
0073A		<1%	55	$3K
88360		<1%	363	$3K
ATP13		<1%	367	$2K
99497		<1%	119	$2K
J3371	Injection, vancomycin hcl (mylan), not therapeutically equivalent to j3370, 500 mg	<1%	1,855	$2K
83937		<1%	206	$2K
11057		<1%	13	$2K
J0136	Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg	<1%	614	$2K
J1836	Injection, metronidazole, 10 mg	<1%	1,181	$2K
86778		<1%	223	$2K
83020		<1%	217	$2K
80185		<1%	393	$2K
86341		<1%	159	$2K
87209		<1%	167	$2K
84478		<1%	1,340	$2K
J1956	Injection, levofloxacin, 250 mg	<1%	29	$2K
87269		<1%	232	$2K
97750		<1%	77	$2K
81050		<1%	1,397	$2K
84075		<1%	2,894	$2K
82955		<1%	244	$2K
86231		<1%	189	$2K
85060		<1%	554	$2K
87497		<1%	194	$2K
64642		<1%	12	$2K
L3908	Wrist hand orthosis, wrist extension control cock-up, non molded, prefabricated, off-the-shelf	<1%	656	$2K
80175		<1%	229	$2K
90887		<1%	220	$2K
69209		<1%	63	$2K
86769		<1%	39	$2K
G2212	Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or qualified healthcare professional, with or without direct patient contact (list separately in addition to cpt codes 99205, 99215, 99483 for office or other outpatient evaluation and management services) (do not report g2212 on the same date of service as 99358, 99359, 99415, 99416). (do not report g2212 for any time unit less than 15 minutes)	<1%	432	$2K
80178		<1%	410	$2K
93797		<1%	35	$2K
90675		<1%	27	$2K
76376		<1%	2,688	$2K
J7060	5% dextrose/water (500 ml = 1 unit)	<1%	2,775	$2K
19301		<1%	14	$2K
86036		<1%	549	$2K
86015		<1%	348	$2K
99152		<1%	702	$2K
92593		<1%	24	$1K
J9267	Injection, paclitaxel, 1 mg	<1%	1,061	$1K
J1940	Injection, furosemide, up to 20 mg	<1%	3,933	$1K
87350		<1%	207	$1K
J0461	Injection, atropine sulfate, 0.01 mg	<1%	552	$1K
90678		<1%	205	$1K
96900		<1%	91	$1K
0164A		<1%	30	$1K
31237		<1%	29	$1K
93284		<1%	82	$1K
0173A		<1%	39	$1K
82465		<1%	859	$1K
88312		<1%	402	$1K
99406		<1%	109	$1K
57160		<1%	24	$1K
71101		<1%	70	$1K
92285		<1%	227	$1K
J1920	Injection, labetalol hydrochloride, 5 mg	<1%	399	$1K
82166		<1%	37	$1K
92235		<1%	12	$1K
A4215	Needle, sterile, any size, each	<1%	1,232	$1K
V5266	Battery for use in hearing device	<1%	54	$1K
82523		<1%	211	$1K
76825		<1%	622	$1K
0094A		<1%	49	$1K
J0134	Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg	<1%	174	$1K
84144		<1%	94	$1K
80156		<1%	131	$1K
85240		<1%	68	$1K
J9190	Injection, fluorouracil, 500 mg	<1%	4,531	$980.90
73000		<1%	67	$979.62
93320		<1%	1,497	$976.46
87177		<1%	155	$975.59
J3480	Injection, potassium chloride, per 2 meq	<1%	5,027	$967.45
94250		<1%	12	$967.02
83718		<1%	175	$949.24
86308		<1%	224	$943.62
G0439	Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit	<1%	38	$940.38
83930		<1%	264	$915.80
87593		<1%	13	$892.50
99417	Prolong home eval add 15m	<1%	1,727	$891.12
95249		<1%	85	$882.00
86256		<1%	145	$876.48
0174A		<1%	41	$825.66
85049		<1%	398	$822.18
76377		<1%	480	$811.97
90687		<1%	1,678	$779.24
ATP19		<1%	80	$764.90
91306		<1%	9,349	$756.40
36592		<1%	160	$752.81
84155		<1%	1,262	$716.93
92556		<1%	37	$705.30
82172		<1%	64	$655.59
11901		<1%	12	$650.02
97012		<1%	19	$622.79
93786		<1%	52	$621.41
76827		<1%	616	$611.02
86905		<1%	227	$602.52
83695		<1%	36	$594.96
95250		<1%	26	$585.81
95165	Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, multiple dose vials	<1%	40	$583.23
86317		<1%	92	$567.22
H0033	Oral medication administration, direct observation	<1%	794	$565.11
L4360	Walking boot, pneumatic and/or vacuum, with or without joints, with or without interface material, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise	<1%	87	$557.20
88302		<1%	254	$550.15
85246		<1%	29	$547.36
85245		<1%	29	$547.36
J9250	Methotrexate sodium, 5 mg	<1%	53	$545.66
96132		<1%	95	$541.68
Q2035	Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (afluria)	<1%	294	$502.03
84157		<1%	258	$479.83
84446		<1%	57	$469.98
82085		<1%	128	$446.38
86258		<1%	40	$444.12
U0001	Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel	<1%	20	$437.27
85014		<1%	314	$428.35
83935		<1%	142	$419.60
85055		<1%	15	$409.76
95885		<1%	14	$388.17
A9561	Technetium tc-99m oxidronate, diagnostic, per study dose, up to 30 millicuries	<1%	216	$386.98
73660		<1%	39	$380.91
89320		<1%	126	$380.88
73522		<1%	14	$380.42
82164		<1%	61	$376.50
91307		<1%	3,639	$361.20
91319		<1%	12	$351.12
G0444	Annual depression screening, 5 to 15 minutes	<1%	123	$346.11
93226		<1%	49	$339.96
Q0091	Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory	<1%	401	$338.02
93922		<1%	13	$337.50
73521		<1%	12	$334.63
97168		<1%	14	$329.16
L1902	Ankle orthosis, ankle gauntlet or similar, with or without joints, prefabricated, off-the-shelf	<1%	12	$322.79
J1010	Injection, methylprednisolone acetate, 1 mg	<1%	1,379	$321.94
95874		<1%	27	$314.45
Q0164	Prochlorperazine maleate, 5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen	<1%	2,847	$308.54
82365		<1%	31	$305.76
A9579	Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml	<1%	2,030	$295.79
86381		<1%	26	$291.85
J9999	Not otherwise classified, antineoplastic drugs	<1%	1,945	$289.20
71110		<1%	17	$289.13
96116		<1%	13	$284.42
82140		<1%	33	$275.63
82945		<1%	116	$254.10
86707		<1%	25	$248.65
90836		<1%	17	$246.60
Q0111	Wet mounts, including preparations of vaginal, cervical or skin specimens	<1%	41	$244.45
96137		<1%	38	$240.00
95700		<1%	187	$237.64
86789		<1%	35	$222.60
86788		<1%	35	$220.80
91303		<1%	2,575	$219.66
82232		<1%	41	$217.13
82952		<1%	61	$211.92
J7042	5% dextrose/normal saline (500 ml = 1 unit)	<1%	445	$208.90
99172		<1%	890	$198.04
82595		<1%	52	$196.42
J0692	Injection, cefepime hydrochloride, 500 mg	<1%	308	$195.87
A9609	Fludeoxyglucose f18 up to 15 millicuries	<1%	591	$195.20
C1713	Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	<1%	38	$185.08
L8000	Breast prosthesis, mastectomy bra, without integrated breast prosthesis form, any size, any type	<1%	947	$184.04
A4300	Implantable access catheter, (e.g., venous, arterial, epidural subarachnoid, or peritoneal, etc.) external access	<1%	26	$183.51
86382		<1%	12	$178.92
82542		<1%	13	$167.58
J2470	Injection, pantoprazole sodium, 40 mg	<1%	229	$167.14
87185		<1%	38	$162.73
17003		<1%	13	$162.50
90749		<1%	13	$162.38
87420		<1%	13	$159.51
76001		<1%	78	$157.66
J2795	Injection, ropivacaine hydrochloride, 1 mg	<1%	101	$152.57
88363		<1%	16	$142.14
J1953	Injection, levetiracetam, 10 mg	<1%	201	$141.36
J1817	Insulin for administration through dme (i.e., insulin pump) per 50 units	<1%	2,008	$136.77
J1756	Injection, iron sucrose, 1 mg	<1%	64	$135.78
82340		<1%	60	$132.80
0171A		<1%	31	$129.83
J0360	Injection, hydralazine hcl, up to 20 mg	<1%	118	$121.89
80329		<1%	1,276	$115.50
87206		<1%	41	$114.00
96381		<1%	227	$110.88
80051		<1%	149	$105.17
82180		<1%	30	$104.64
91300		<1%	23,082	$103.21
J7510	Prednisolone oral, per 5 mg	<1%	55	$89.36
87181		<1%	13	$87.99
86880		<1%	25	$86.46
87449		<1%	25	$80.93
70360		<1%	12	$79.44
J2560	Injection, phenobarbital sodium, up to 120 mg	<1%	115	$71.00
G0105	Colorectal cancer screening; colonoscopy on individual at high risk	<1%	15	$62.43
90696		<1%	2,096	$62.41
90633		<1%	5,407	$54.25
85260		<1%	13	$48.99
86702		<1%	15	$43.56
81015		<1%	16	$40.35
99153	Mod sedat endo service >5yrs	<1%	771	$37.47
86701		<1%	15	$36.64
69200		<1%	12	$35.76
30901		<1%	13	$34.24
G1004	Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program	<1%	3,304	$29.38
90611		<1%	68	$25.80
87210		<1%	15	$23.33
99606		<1%	22	$21.50
91305		<1%	1,241	$16.90
87176		<1%	13	$15.57
J1596	Injection, glycopyrrolate, 0.1 mg	<1%	556	$8.47
98941	Chiropractic manipulative treatment; spinal, 3-4 regions	<1%	17	$7.08
C9113	Injection, pantoprazole sodium, per vial	<1%	1,620	$6.82
A6209	Foam dressing, wound cover, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing	<1%	41	$4.44
91313		<1%	4,080	$4.37
91312		<1%	3,724	$0.01
Q0220	Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 300 mg	<1%	192	$0.01
90700		0%	3,010	$0.00
90710		0%	1,939	$0.00
G9011	Coordinated care fee, risk adjusted maintenance, level 5	0%	26,094	$0.00
T2024	Service assessment/plan of care development, waiver	0%	6,936	$0.00
90681		0%	5,734	$0.00
Q9966	Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml	0%	717	$0.00
J2919	Injection, methylprednisolone sodium succinate, 5 mg	0%	324	$0.00
G8978	Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals	0%	1,540	$0.00
96113		0%	1,637	$0.00
J9000	Injection, doxorubicin hydrochloride, 10 mg	0%	197	$0.00
90648		0%	2,737	$0.00
90685		0%	286	$0.00
90690		0%	15	$0.00
G9004	Coordinated care fee, risk adjusted low, initial	0%	863	$0.00
T2038	Community transition, waiver; per service	0%	330	$0.00
G0390	Trauma response team associated with hospital critical care service	0%	107	$0.00
78434		0%	13	$0.00
G0500	Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate)	0%	250	$0.00
M0247	Intravenous infusion, sotrovimab, includes infusion and post administration monitoring	0%	18	$0.00
91311		0%	322	$0.00
G8979	Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting	0%	1,695	$0.00
91308		0%	743	$0.00
G8985	Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting	0%	369	$0.00
88344		0%	12	$0.00
J1450	Injection fluconazole, 200 mg	0%	144	$0.00
G9919	Screening performed and positive and provision of recommendations	0%	143	$0.00
J1171	Injection, hydromorphone, 0.1 mg	0%	217	$0.00
G8984	Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals	0%	343	$0.00
L1820	Knee orthosis, elastic with condylar pads and joints, with or without patellar control, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise	0%	28	$0.00
G8996	Swallowing functional limitation, current status at therapy episode outset and at reporting intervals	0%	123	$0.00
J3473	Injection, hyaluronidase, recombinant, 1 usp unit	0%	16	$0.00
G8997	Swallowing functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting	0%	110	$0.00
96133		0%	38	$0.00
94664		0%	28	$0.00
A9541	Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries	0%	12	$0.00
93356		0%	13	$0.00
94375		0%	26	$0.00
G8989	Self care functional limitation, discharge status, at discharge from therapy or to end reporting	0%	13	$0.00
Q9961	High osmolar contrast material, 250-299 mg/ml iodine concentration, per ml	0%	12	$0.00
96136		0%	24	$0.00
72202		0%	16	$0.00
99221		0%	20	$0.00
75565		0%	12	$0.00
90380		0%	38	$0.00
J1631	Injection, haloperidol decanoate, per 50 mg	0%	15	$0.00
94761		0%	122	$0.00
G8980	Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting	0%	507	$0.00
80320		0%	1,627	$0.00
90744		0%	3,354	$0.00
90680		0%	413	$0.00
G0506	Comprehensive assessment of and care planning for patients requiring chronic care management services (list separately in addition to primary monthly care management service)	0%	1,252	$0.00
J8501	Aprepitant, oral, 5 mg	0%	551	$0.00
C1725	Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability)	0%	28	$0.00
91309		0%	48	$0.00
90657		0%	246	$0.00
G9005	Coordinated care fee, risk adjusted maintenance	0%	48,340	$0.00
G9007	Coordinated care fee, scheduled team conference	0%	693	$0.00
73600		0%	14	$0.00
90697		0%	3,522	$0.00
91316		0%	30	$0.00
J1805	Injection, esmolol hydrochloride, 10 mg	0%	109	$0.00
91317		0%	228	$0.00
J2003	Injection, lidocaine hydrochloride, 1 mg	0%	12	$0.00
G8988	Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting	0%	45	$0.00
78320		0%	46	$0.00
J7611	Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg	0%	49	$0.00
90619		0%	58	$0.00
J1921	Injection, labetalol hydrochloride (hikma), not therapeutically equivalent to j1920, 5 mg	0%	14	$0.00
J3590	Unclassified biologics	0%	247	$0.00
91315		0%	442	$0.00
J2920	Injection, methylprednisolone sodium succinate, up to 40 mg	0%	13	$0.00
90698		0%	268	$0.00
G0416	Surgical pathology, gross and microscopic examinations, for prostate needle biopsy, any method	0%	79	$0.00
99402		0%	54	$0.00
73120		0%	12	$0.00
J3357	Ustekinumab, for subcutaneous injection, 1 mg	0%	13	$0.00
90381		0%	161	$0.00
J2020	Injection, linezolid, 200 mg	0%	42	$0.00
95831		0%	25	$0.00
J0611	Injection, calcium gluconate (wg critical care), per 10 ml	0%	30	$0.00
G8987	Self care functional limitation, current status, at therapy episode outset and at reporting intervals	0%	44	$0.00
Q0221	Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 600 mg	0%	60	$0.00
96380		0%	22	$0.00
Q9963	High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml	0%	13	$0.00
C9399	Unclassified drugs or biologicals	0%	21	$0.00
J0604	Cinacalcet, oral, 1 mg, (for esrd on dialysis)	0%	28	$0.00
54235		0%	14	$0.00
G0123	Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision	0%	91	$0.00
96377		0%	21	$0.00
88331		0%	14	$0.00
J0456	Injection, azithromycin, 500 mg	0%	17	$0.00
A9597	Positron emission tomography radiopharmaceutical, diagnostic, for tumor identification, not otherwise classified	0%	13	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialHOLLENBERG, ANTHONY (PRESIDENT)

Same official

Other billing entities under HOLLENBERG, ANTHONY

Full network →

Provider	Location	Paid
Boston Medical Center Corporation	Boston, MA	$13K

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.